Table 1.
In vitro susceptibility of clinical isolatesoffive farms and morbidityofincidencerate.
| Farms | Species | No. of isolates | incidence rate | No. of resistance isolates | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ENR | FFC | CEQ | TET | DOX | SXT | GEN | TIL | ||||
| CC | Escherichia coli | 10 | 0.01% | 3 | 1 | 6 | 1 | 1 | 1 | ||
| BC | Escherichia coli | 20 | 0.02% | 2 | 1 | 1 | 4 | 2 | 3 | 1 | |
| GZL | Escherichia coli | 5 | 0.5% | 3 | 4 | 1 | 3 | 4 | 5 | 5 | 5 |
| CL | Escherichia coli | 67 | 7.0% | 23 | 12 | 7 | 49 | 54 | 59 | 25 | 22 |
| Aeromonastrota | 3 | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 1 | ||
| YJ | Streptococcus | 17 | 12.0% | 4 | 6 | 3 | 9 | 14 | 17 | 7 | 4 |
| Escherichia coli | 56 | 21 | 16 | 5 | 25 | 41 | 51 | 40 | 32 | ||
| clostridiumwelchii | 3 | 1 | 3 | 3 | 3 | ||||||
| Moraxellalacunata | 2 | 2 | 1 | 2 | 3 | 2 | 2 | ||||
| PlesiomonasShigeloides | 4 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | |||
ENR, enrofloxacin; FFC, florfenicol; CEQ, cefotaxime; TET, tetracycline; DOX, doxycycline; SXT, sulfamethoxazole/trimethoprim. GMS, gentamicin; TIL, tilmicosin.